$EBS Income Statement | Understand Stock

$EBS

$7.09 +$0.42 (6.3%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues:
Cost of Commercial Product sales
Commercial Product sales
Cost of MCM Product sales
Services
Total cost of Commercial Product sales
Product and services sales, net
Contracts and grants
Total revenues
Leases
Leases
Leases
Total leases

Total Bioservices revenues
Total CDMO
Total Bioservices revenues

Operating expenses:
Cost of product and services sales, net
Cost of Commercial Product sales
CDMO
Commercial Product sales
Cost of MCM Product sales
Total CDMO

Total Bioservices revenues
Total cost of product and services sales, net

Research and development
Selling, general and administrative
Amortization of intangible assets
Goodwill impairment
Impairment of long-lived assets
Total operating expenses
Income (loss) from operations
Other income (expense):
Interest expense
Gain on sale of business
Gain (loss) on extinguishments of debt
Other, net
Total other income (expense), net
Income (loss) before income taxes
Income tax provision
Net income (loss)
Earnings (loss) per common share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted average shares outstanding
Basic (in shares)
Diluted (in shares)

Comments